Physician profile
Corey G Persons
NPI 1356498828
$852.06
in general payments reported to CMS, 2019-2025
12 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $12.27 · 2021: $59.36 · 2022: $70.71 · 2023: $147 · 2024: $50.48 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $184.12 | 2019-2024 | Acrysof Iq Panoptix Uv Iol, Total30, Rocklatan |
| Biotissue Holdings INC. | $116.59 | 2025 | |
| Johnson & Johnson Vision Care, INC. | $94.75 | 2019-2025 | Acuvue |
| Dompe US, INC. | $93.57 | 2024-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $77.48 | 2025 | Acthar |
| Abbvie INC. | $75.31 | 2025 | |
| Bausch & Lomb Americas INC. | $60.22 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.21 | 2019-2021 | |
| Coopervision INC. | $47.07 | 2019-2021 | |
| Astellas Pharma US INC | $23.34 | 2025 | Izervay |
| Oyster Point Pharma, INC. | $16.89 | 2023 | Tyrvaya |
| Shire North American Group INC | $13.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Persons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.